Cambridge, Mass. – December 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity (prucalopride), a once-daily, oral treatment option for adults with Chronic…Original Article
FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)
